You are here: Industry Insights > SPI

News List

SPI Pharma Launches UltraBurst contractpharma
July 13, 2021
SPI Pharma has introduced UltraBurst, providing a step-change in the most critical orally disintegrating tablet (ODT) characteristics—dissolution time. It is an innovative excipient platform for flash ODTs, enabling disintegration in under ten seconds.
CPhI Webinar: Trends and Advances in Patient Centric Drug Development - Watch On Demand cphi-online
June 24, 2021
Catch up on the latest trends and developments in patient centric drug development
Sound Pharmaceuticals Receives $3.1M NIH Grant for COVID Treatment contractpharma
April 08, 2021
Sound Pharmaceuticals, Inc. (SPI) has received a Cooperative Grant award from the National Center for Advancing Translational Sciences (NCATS) at the NIH for $3.1 milion to support the testing of SPI-1005 in two Phase 2 clinical trials for the ...
FDA Clears SPI’s Ebselen for Phase II COVID-19 Trials contractpharma
September 01, 2020
SPI-1005 is a novel anti-inflammatory drug which was recently shown to inhibit nCoV2 activity and viral replication.